dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· June 30, 2026

Eos Announces Pricing of Registered Direct Offering of Common Stock and Warrants to Fund Investment in Frontier Power USA

View original at globenewswire.com
Eos Announces Pricing of Registered Direct Offering of Common Stock and Warrants to Fund Investment in Frontier Power USA EDISON, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The FPUSA platform model is expected to drive increased demand for Eos' Z3 technology and enhance the Company's ability to participate in the long-term value generated by project deployments.

    60% confidence
  • Eos expects to use the net proceeds from the Offering as well as any proceeds from its proposed rights offering to fund its contribution to Frontier Power USA Parent, LLC.

    60% confidence
  • Under FPUSA's planned financing model, the equity base is expected to support more than $1.5 billion of deployable project capital at approximately 75% loan-to-value.

    60% confidence
  • FPUSA has a robust pipeline of approximately 16 GWh of long-duration energy storage projects across key U.S. markets, of which approximately 2.7 GWh represents high-probability conversion opportunities, including approximately 1.2 GWh expected to be ready to sign.

    60% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Eos Announces Pricing of Registered Direct Offering of Common Stock and Warrants to Fund Investment in Frontier Power USA: Source | Via News | fr.via.news